Elsevier has created a [Monkepox Information Center](#) in response to the declared public health emergency of international concern, with free information in English on the monkeypox virus. The Monkeypox Information Center is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its monkeypox related research that is available on the Monkeypox Information Center - including this research content - immediately available in publicly funded repositories, with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the Monkeypox Information Center remains active.
Mpqox and pregnancy: A neglected disease and its impact on perinatal health

M.A. Velázquez-Cervantes, J.M. Ulloa-Aguilar, M. León-Juárez

Departamento de Inmuno-bioquímica, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Ciudad de México, Mexico

Received 31 July 2022; accepted 14 September 2022

Abstract  Viral infections during pregnancy have been one of the leading causes associated with significant perinatal problems, such as congenital defects, fetal neurological syndromes, stillbirths, and adverse pregnancy outcomes. The mpox virus infection, caused by an Orthopoxvirus related to the human smallpox virus, was declared a global health emergency by the World Health Organization in July 2022 due to the large number of cases emerging outside the usual endemic area in Africa. There is little information on the impact of mpox virus infection during pregnancy, although the limited evidence available shows a high rate of fetal harm. This review addresses the problem of mpox virus infection in pregnant women and provides indications for its prevention, diagnosis, and treatment.

© 2022 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved.

La viruela del mono y el embarazo: una enfermedad olvidada y su impacto en la salud perinatal

Resumen  Las infecciones virales durante el embarazo han sido una de las principales causas asociadas a problemas perinatales de gran importancia como lo son daños congénitos, síndromes neurológicos fetales, abortos y desencadenantes adversos de la gestación. La infección por el virus de viruela del mono, causada por un Orthopoxvirus emparentado con el virus de la viruela humana, ha sido declarada por la Organización Mundial de la Salud en julio de 2022 una emergencia de salud global ante el gran número de casos surgidos fuera del área endémica habitual en África. Existe poca información sobre el impacto de la infección por el virus de la viruela del mono.

* Corresponding author.

E-mail address: moisesleoninper@gmail.com (M. León-Juárez).

https://doi.org/10.1016/j.rceng.2022.09.002

2254-8874/© 2022 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved.
Introduction

Multiple cases of mpx have been reported in recent months in areas of the world where the disease is not endemic. In July 2022, the World Health Organization (WHO) declared the outbreak of infections caused by the virus a global Public Health Emergency, with close to 16,836 cases across 74 countries (Fig. 1). Clinical evidence regarding mpx virus infection in pregnancy is limited, primarily due to the socio-economic situations and civil conflicts in many of the countries where this viral infection is endemic. Therefore, it is important to create and document new medical literature regarding possible vertical transmission and the effects on the health of the mother-baby pair.

In this regard, the following review focuses on the existing evidence of the effects of mpx infection during pregnancy, as well as clinical and prophylactic recommendations such as vaccination, and the hypothesis of a placenta effect via maternal infection that this emerging virus could disrupt positive outcomes during gestation.

Clinical and virological characteristics of the mpx virus

Mpx virus is belongs to the Orthopoxvirus genus of the Poxviridae family. Structurally, these viruses are oval shaped and between 200 and 400 nm in length. These viruses have a complex capsid architecture, containing 100 different proteins and their genome, a double chain deoxyribonucleic acid (DNA), contains approximately between 133 and 229 genes. The genome replicates in the cytoplasm of the host cell.

Epidemiological studies state that the mpx virus was first identified in a group of macaques imported from Singapore in 1958. Zoonotic infection in humans was not identified until 1970 when the first case was reported in the Democratic Republic of the Congo.

Epidemiological studies have identified the genetic diversity of the virus, suggesting the presence of 2 clades depending on their geographic distribution: the west African clade, associated with cases in other areas where the infection is not endemic and the case fatality rate is less than 1%, and the central African clade (Congo Basin), which is more virulent and has a case fatality rate of 10%.

Since it was first detected, this pathogen has been endemic to eastern and central Africa, with thousands of cases reported annually in this part of the world. Cases were imported from the African continent in 2003 with infections in the United States, United Kingdom, and Singapore. Currently, close to 16,000 cases of individuals infected with mpx have been detected in different parts of Europe and North America.

Circulation of the virus in people from different areas of the planet that have not travelled to endemic regions suggests the possibility of human dissemination through zoonotic contact with species that have the virus, thus facilitating subsequent horizontal transmission.

Mpx virus is maintained in different animals that act as reservoirs and has primarily been identified in small rodents and non-human primates. Human infection can occur due to direct contact with the infected animal or due to exposure to fluids from the infected animal, such as blood. Infection can also occur through animal bites and, possibly, via the consumption of these animals associated with customs in rural communities in Africa.

Horizontal transmission between humans is the most common route of infection for the virus, mainly through contact with the skin lesions the infection causes, with secondary lesions due to autoinfection, and through contact with shared infected objects and areas.

Possible sexual transmission of mpx virus has been suggested based on the fact that the majority of the cases have presented in subjects without any history of travel to endemic areas and who have had close contact with symptomatic individuals. Characteristically, skin lesions are observed in the genital or perianal areas together with regional adenopathies. While more studies are still needed, it is possible for this route of transmission to occur.

Clinical manifestations associated with mpx virus infection have been characterised by lasting approximately 2–5 weeks, with an estimated incubation period of 5–21 days. Signs and symptoms include: fever, headache, lymphadenopathy, myalgia, and skin manifestation such as macules, papules, vesicles and pustules which appear during a period of 5 days after the fever. Risk of infection is greater in the presence of skin lesions, however the possibility of transmission through asymptomatic individuals has not been ruled out.

Mpx, unlike smallpox, has a mortality rate of less than 1%, which mainly affects children and young adults. Individuals with some immunodeficiency have been identified to be more vulnerable to developing more severe disease and thus present a higher case fatality rate.
Figure 1  Map of confirmed cases of mpox since the first reported infections starting on 1 January 2022 up to 25 July 2022. Highlighted in red: United States, Spain, Germany, Unite Kingdom, and France, the countries most affected by virus transmission. In orange, those with a high chance of infection. In yellow, those with a low number of recorded cases. Made with https://mapchart.net/world.html.

Figure 2  Transmission of the mpox virus. The natural reservoirs for the virus are thought to be tree- and land-dwelling rodents, where the virus is then transmitted between the rodents and non-human primates. It has been observed that these animal species are capable of transmitting and infecting humans through respiratory droplets, sexual transmission, contact with skin lesions and vertical transmission. The primary symptoms of mpox infection are fever, headache, myalgia, intense asthenia, and skin rash. The main difference from smallpox is the lymphadenopathy that the infection causes.

Evidence of mpox during pregnancy

We have limited information on the impact in pregnant women of infection with this emerging virus. In addition, the majority of the natural history of infection has occurred in Africa in areas with social inequality, civil wars, and other social factors that limit potential monitoring or follow-up. Nevertheless, the few existing clinical studies have produced results that clearly show that mpox can be transmitted vertically. The WHO reports vertical transmission
of mpox via the placenta, which can cause congenital infection, or infection can occur due to direct contact during or after birth (Fig. 2).\textsuperscript{21}

The evidence supporting this idea has been established in an observational study in a cohort of 222 individuals admitted to a hospital in the Democratic Republic of the Congo: all the patients presented clinical signs and symptoms of mpox. Four pregnant women were identified during the study: three experienced foetal death and only one reached full-term and birthed a healthy baby.

Interestingly, among the gestational losses, two of the women presented with moderate-to-severe disease, which was associated with spontaneous miscarriage in the first trimester. The third woman, also with moderate-to-severe disease, in her 18th week of gestation, experienced intrauterine demise of the foetus. The foetus showed clear manifestations of mpox infection (cutaneous maculopapular lesions involving the trunk, head, palms and soles of the hands and feet); the presence of hydrops fetalis was detected, as well as hepatomegaly with peritoneal effusion. There were no congenital malformations nor was any damage to the placenta, foetal membranes, or umbilical cord observed. However, molecular testing identified virus DNA in foetal and placental tissue, confirming vertical transmission of the virus.\textsuperscript{12,13}

The study conducted by Jezek et al.\textsuperscript{24} describes a probable, non-laboratory-confirmed case of perinatal mpox infection: a pregnant woman at 24 weeks’ gestation with mpox infection who, after 6 weeks, delivered a premature infant that presented with generalized skin rash suggestive of the presence of the infection. Ultimately, the child died 6 weeks later of malnutrition (Fig. 3).

The clinical evidence has described the significance of the effect had by a member of the \textit{poxvirus} most related to humans, such as the smallpox virus, which has greater morbidity and mortality among pregnant women as compared to women who are not pregnant.\textsuperscript{25} As well, the effect of this infection within the perinatal context is related to a higher proportion of cases of preterm labour, premature birth and spontaneous abortion. Therefore, foetal deaths observed in mpox cases should not be considered an isolated event.\textsuperscript{16}

More clinical and experimental evidence is needed to understand the placental infection processes and how this can disrupt gestation and lead to foetal death.

With this review, we hope to shine a spotlight on the harm caused by viral infections during human gestation. It has already been shown how these pathogens play a significant role in disrupting the mother-baby pair, by producing an adverse clinical condition for the foetus, or damage to the placenta, caused by maternal infection, which culminates in the physiology of the pregnancy being affected.

Other emerging viruses, such as Zika, have shown that in-utero infections can be associated with congenital malformations and foetal neurological defects that result in poor quality of life for the neonate or even death.\textsuperscript{27,28} Vertical transmission of other pandemic viruses, such as SARS-CoV-2, remain a controversial topic. The clinical evidence has shown an increase in complications during gestation, such as the onset of pre-eclampsia, preterm labour, and foetal death.\textsuperscript{29,30}

Maternal infection can also lead to vascular and inflammatory lesions in the placenta that promote poor placental vascular perfusion and may be associated with the development of pre-eclampsia.\textsuperscript{31}

While more studies are needed to understand the impact of SARS-CoV-2 infection during gestation, it is important to report this evidence to verify that these emerging viruses are pathogenic agents that may potentially cause pandemics. Pregnant women must be considered a vulnerable population in light of these pathogens and, therefore, at-risk. The same is true for pregnant women and the novel mpox infection.

**Recommendations for diagnosing and treating mpox during pregnancy**

In terms of the general population, the recommendation is to avoid skin-to-skin contact with individuals with a skin rash that could be suggestive of mpox virus infection, to avoid contact with objects and materials that have been used by a mpox patient and, lastly, hand washing before eating and using the bathroom.\textsuperscript{21,32-34}

Likewise, the Centre for Disease Control and Prevention (CDC) has a series of recommendations for pregnant women. In the event that a woman has been exposed to the virus, she should be monitored for the appearance of symptoms. If symptoms do appear, the patient should isolate at home or in a health care setting depending on the severity of her symptoms. The differential diagnosis of the skin lesions may be broad at the start and include other sexually transmitted infections or skin rash infections. Patients should remain in isolation until all lesions have resolved, the scabs have fallen off, and a fresh layer of intact skin has formed.\textsuperscript{35}

Reproductive decisions should be reconsidered during mpox infection. While the evidence for the perinatal impact of this infection remains under study, pregnancy planning can be delayed until the risk of infection is minimal.\textsuperscript{36}

Again, experience with the COVID-19 pandemic has provided guidelines for being prepared and generating clinical and diagnostic algorithms that, together, help us improve care for pregnant women infected with mpox virus.

Dashraath et al.\textsuperscript{21} propose guidelines for monitoring pregnant women with mpox virus infection. The guidelines include clinical diagnosis based on the presence of compatible signs and symptoms, including sore throat or genital or analorectal pain, presence of regional lymphadenopathies and vesiculopustular rash, as well as recommendations for the diagnosis of biological samples (skin lesion exudates) via PCR. Differential diagnosis of the mpox clinical picture may also include infection by other pathogens such as varicella-zoster, herpes simplex, or syphilis.

If mpox virus infection is confirmed, isolation and hospitalisation in a health care setting with negative pressure rooms is indicated. Ultrasound foetal monitoring is advisable to identify anomalies such as foetal hepatomegaly or hydrops (Fig. 4).\textsuperscript{15,36}

There is currently no specific antiviral therapy for mpox infection in pregnant women. The United States Food and Drug Administration (FDA) has tested some antiviral drugs for the treatment of mpox infection.

Tecovirimat, from SIGA Technologies laboratory, also recognised by the CDC, is an antiviral that inhibits orthopoxviruses by blocking the VP37 envelope wrapping
Figure 3  Vertical transmission. In the few studies of this infection in maternal-fetal setting, it has been shown that mpox virus transmission can cause clinical manifestations in babies such as hydrops fetalis, maculopapular skin lesions on the body, hepatomegaly, and premature birth.

Figure 4  Clinical proposal for managing pregnant women with suspected mpox virus infection. Diagram of the management stages for pregnant patients with mpox virus infection or suspected infection and clinical follow-up that should be implemented in these cases to prevent complications with foetal development or the patient.

protein. Currently there are no human data for its use during pregnancy: there are only two data on its impact in the gestational setting in animal models and with a dose that is 23 times higher than in humans, though no adverse effects were observed. Nevertheless, it can cause hypoglycaemia in patients with type 2 diabetes being treated with repaglinide. Tecovirimat is administered as one 600 mg capsule twice per day for 2 weeks, while the injectable presentation is recommended every 6 h for 2 weeks. Some adverse reactions have been reported for the oral route (at least 2% of tests in humans), with headache, nausea, abdominal pain, and vomiting; via injection, less than 4% presented with injection site reactions and headache.35-37

Another drug alternative may be brincidofovir, an inhibitor that acts on the DNA polymerase of various bicalentary DNA viruses such as mpox. Nevertheless, administration of any of these drugs is only recommended when patients present severe complications.33 Another option could be the administration of vaccinia immune globulins, a cocktail of purified antibodies from individuals immunized with the smallpox vaccine. While there is no clear evidence regarding their efficacy for mpox infection during pregnancy, the
use of immune globulins has been widely documented in other diseases during pregnancy, verifying their safety and efficacy.38

**Vaccination, a plan to prevent mpopx infection during pregnancy**

The safety and efficacy of vaccine use in pregnant women has been a topic of debate given that the majority of clinical studies do not include pregnant women. The few existing clinical studies have observed that vaccination during pregnancy has a dual beneficial effect: it prevents infection in the mother and protects the newborn.39 Nevertheless, there are still risks, and the benefits and potential adverse effects must be assessed.40

At present, pregnant women are one of the groups of interest during the recent mpopx outbreak as it has been seen that vertical transmission is possible. Therefore, maternal vaccination should be considered as a way to control intrauterine infection.

The data generated by studies addressing the role of acquired immunization via vaccination against smallpox have shown that there is a protective effect against mpopx virus infection, as clinical manifestations of the diseases are prevented. The CDC currently recommends the use of two vaccines to protect against mpopx: JYNNEOS (MVA-BN), a non-replicating viral vaccine of modified vaccinia Ankara, and ACAM2000, a second-generation vaccine derived from the live Dryvax virus.

In the case of MVA-BN, from the laboratory Bavarian Nordic, there is insufficient data in pregnant women to determine whether it presents a risk to this population group. No evidence of foetal demise was observed in animal models. It is administered via intramuscular injection in 2 doses (0.5 mL) with 4 weeks between each dose. Local reactions can appear following administration, such as pain at the injection site, redness, swelling, induration, and itching and systemic effects such as myalgia, headache, fatigue, nausea, and chills.41

On the other hand, the ACAM2000 vaccine, from Emergent Product Development Gaithersburg Inc. laboratories, is administered intradermally. One of the reactions that occurs 3 or 4 days after vaccination is the formation of a red blister that causes skin irritation. This blister ultimately turns into a scab that takes approximately 3 weeks to fall off.42

Administration of the replicating ACAM2000 vaccine is contraindicated in pregnant or breastfeeding women because congenital defects can occur in the foetus and infections can occur in the foetus or new-born. Therefore, women vaccinated with ACAM2000 are advised to not fall pregnant for 4 weeks or until the blister has healed and the scab has fallen off.43

Therefore, pregnant women who have come into contact with mpopx and are considered to be at risk are left with the option of vaccination with the JYNNEOS vaccine, with proven efficacy and protection against infection.34,44

**Conclusion**

Mpopx infection is currently considered a global health concern. Its spread across different countries has activated epidemiological warnings. In addition to immunocompromised patients, pregnant women are considered to be a vulnerable population group. This premise will help initiate protocols to prevent significant involvement of this population group.

Clinical evidence has suggested a strong possibility of vertical mpopx infection during pregnancy, which can cause considerable foetal harm and the potential for fatal outcomes. Some health care strategies, such as social distancing, the use of protective equipment, and reproduction planning, may help prevent infection among this population.

Vaccination of pregnant women in risk settings should be considered as a prophylactic measure that will help ensure a safe gestation.

**Funding**

This article did not receive any type of funding.

**Conflicts of interest**

All the authors declare that they do not have any conflicts of interest.

**References**

1. Kozlov M. Monkeypox goes global: why scientists are on alert. Nature. 2022;606:15-6.
2. 2022 Monkeypox Outbreak Global Map. Available from: https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html?ibclid=IwAR11QHqkt1IxY-yxT3dh7GLaNGDQkgUCQ 3fy61_02xYE9ChEpDUBC4print. [Accessed 25 July 2022].
3. Gong Q, Wang C, Chui X, Chiu S. Monkeypox virus: a re-emerging threat to humans. Virol Sin. 2022. S1995-820X(22)00120-1.
4. Liu L, Cooper T, Howley PM, Hayball JD. From crescent to mature virion: vaccinia virus assembly and maturation. Viruses. 2014;6:3787-808.
5. Kieser Q, Noyce RS, Shououda M, Lin YCJ, Evans DH. Cytoplasmic factories, virus assembly, and DNA replication kinetics collectively constrain the formation of poxvirus recombinants. PLoS One. 2020;15:e0228028.
6. Hrab M, Joumi S, Albitar MM, Alaidi S, Alshehabi Z. The outbreak of monkeypox 2022: an overview. Ann Med Surg (Lond). 2022;79:104069.
7. Kannan S, Shaik Syed Ali P, Sheeza A. Monkeypox: epidemiology, mode of transmission, clinical features, genetic clades and molecular properties. Eur Rev Med Pharmacol Sci. 2022;26:5983-90.
8. Vandenbogaert M, Kwasiorski A, Gonofio E, Descorps-Declère S, Selekou B, Nikili Meyong AA, et al. Nanopore sequencing of a monkeypox virus strain isolated from a pustular lesion in the Central African Republic. Sci Rep. 2022;12:10768.
9. Simpson K, Heymann D, Brown CS, Edmunds WJ, Elsegaard J, Fine P, et al. Human monkeypox — after 40 years, an unintended consequence of smallpox eradication. Vaccine. 2020;38:5077-81.
10. Parker S, Nuara A, Buller RML, Schultz DA. Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2007;2:17-34.
11. Tiete MS, Harrigan RJ, Thomassen HA, Smith TB. Ghosts of infections past: using archival samples to understand a century of monkeypox virus prevalence among host communities across space and time. R Soc Open Sci. 2018;5:171089.
12. Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Prevention and treatment of monkeypox. Drugs. 2022;82:957-63.
13. Vivancos R, Anderson C, Blomquist P, Balasengaram S, Bell A, Bishop L, et al. Community transmission of monkeypox in the United Kingdom, April to May 2022. Euro Surveill. 2022;27, 2200422.

14. Alphalhô M, Frade JV, Sousa D, Patrocinio J, Garrido PM, Correia C, et al. Monkeypox: a new (sexually transmissible) epidemic? J Eur Acad Dermatol Venereol. 2022, doi:10.1111/jdv.18424.

15. Heskyn J, Belfield A, Milne C, Brown N, Walters Y, Scott C, et al. Transmission of monkeypox virus through sexual contact — a novel route of infection. J Infect. 2022. S0163-4453(22)00335-8.

16. Xiang Y, White A. Monkeypox virus emerges from the shadow of its more infamous cousin: family biology matters. Emerg Microbes Infect. 2022;11:1768–77.

17. Schneider KA, Eichner M. Does it matter who is spreading monkeypox? Lancet Infect Dis. 2022. S1473-3099(22)00431-5.

18. Awon MAE, Waseem M, Sahito AF, Sahito AM, Khati G, Butt MA, et al. Monkeypox has devastated the world; should we prepare for the outbreak of a new pandemic? Ann Med Surg (Lond). 2022;79:104051.

19. Jamieson DJ, Cono J, Richards CL, Treadwell TA. The role of the obstetrician-gynecologist in emerging infectious diseases: monkeypox and pregnancy. Obstet Gynecol. 2004;103:754–6.

20. Kisalu NK, Mokili JL. Toward Understanding the Outcomes of monkeypox infection in human pregnancy. J Infect Dis. 2017;216:795–7.

21. Dasrathraath P, Nielsen-Saines K, Mattar C, Musso D, Tambyah P, Baud D. Guidelines for pregnant individuals with monkeypox virus exposure. Lancet. 2022;400:21–2.

22. Khalil A, Samara A, O’Brien P, Morris E, Draycott T, Lees C, et al. Monkeypox and pregnancy: what do obstetricians need to know? Ultrasound Obstet Gynecol. 2022;60:22–7.

23. Mbala PK, Huggins JW, Riu-Rovira T, Ahuka SM, Mulembakani P, Rimoin AW, et al. Maternal and fetal outcomes among pregnant women with human monkeypox infection in the Democratic Republic of Congo. J Infect Dis. 2017;216:824–8.

24. Juez Z, Gromyko AJ, Szczewiowski MV. Human monkeypox. J Hyg Epidemiol Microbiol Immunol. 1983;27:13–28.

25. Suarez VR, Hankins GDV. Smallpox and pregnancy: from eradicated disease to bioterrorist threat. Obstet Gynecol. 2002;100:87–93.

26. Nishiura H. Smallpox during pregnancy and maternal outcomes. Emerg Infect Dis. 2006;12:1119–21.

27. Martins Ronchi DC, Scaranello Malaquias MA, Rebutini PZ, Panini do Carmo LA, Neto PC, Marini ES, et al. Placental morphologic similarities between ZIKV-positive and HIV-positive pregnant women. Front Immunol. 2021;12 [Accessed 23 August 2022] https://www.frontiersin.org/articles/10.3389/fimmu.2021.684194.

28. Kahle KT, Kulkarni AV, Limbrick DD, Warf BC. Hydrocephalus in children. Lancet. 2016;387:788–99.

29. Garcia Rodriguez A, Marcos Contreras S, Fernandez Manovel SM, Marcos Vidal JM, Diez Buron F, Fernandez Fernandez C, et al. SARS-COV-2 infection during pregnancy, a risk factor for eclampsia or neurological manifestations of COVID-19? Case report. BMC Pregnancy Childbirth. 2020;20:587.

30. Sharps MC, Hayes DJL, Lee S, Zou Z, Brady CA, Almoghrabi Y, et al. A structured review of placental morphology and histopathological lesions associated with SARS-CoV-2 infection. Placenta. 2020;101:13–29.

31. Schwartz DA, Morotti D. Placental pathology of COVID-19 with and without fetal and neonatal infection: trophoblast necrosis and chronic histiocytic intervillositis as risk factors for transplacental transmission of SARS-CoV-2. Viruses. 2020;12:E1308.

32. Centers for Disease and Control. How to protect yourself. Available from: http://www.cdc.gov/poxvirus/monkeypox/prevention/protect-yourself.htm. [Accessed 19 September 2022].

33. Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Prevention and treatment of monkeypox. Drugs. 2022;82:957–63.

34. Khalil A, Samara A, O’Brien P, Morris E, Draycott T, Lees C, et al. Monkeypox vaccines in pregnancy: lessons must be learned from COVID-19. The Lancet Global Health. 2022 [Accessed 23 July 2022] https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(22)00284-4/fulltext

35. Clinical considerations for monkeypox in people who are pregnant or breastfeeding. Available from: https://www.cdc.gov/poxvirus/monkeypox/clinicians/pregnancy.html. [Accessed 16 August 2022].

36. Nanda K, Lebetkin E, Steiner MJ, Yacobson I, Dorflinger L.J. Contraception in the era of COVID-19. Glob Health Sci Pract. 2020;8:166–8.

37. TPOXX (TECOVIRIMAT) fact sheet. Available from: https://www.siga.com/wp-content/themes/sigahba/TPOXX-Fact-Sheet.pdf. [Accessed 16 August 2022].

38. Chou YL, Hsieh KH, Perng CL, Fan HC, Tien CH, Wang CC, et al. High level antibodies to TORCH in the IVIG preparation from Taiwanese. J Chin Med Assoc. 2019;82:510–4.

39. Simionescu AA, Streinu-Cercel A, Popescu FD, Stanescu AMA, Vieru M, Danclu BM, et al. Comprehensive overview of vaccination during pregnancy in Europe. J Pers Med. 2021;11:1196.

40. Arora M, Lakshmi R. Vaccines - safety in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2021;76:23–40.

41. Hosier H, Farhadian SF, Morotti RA, Deshmukth U, Lu-Culligan A, Campbell KH, et al. SARS-CoV-2 infection of the placenta. J Clin Invest. 2020;130:4947–53.

42. Pack Insert- JYNNEOS. Available from: https://www.fda.gov/media/131078/download. [Accessed 17 August 2022].

43. Centers for Disease Control and Prevention Monkeypox Pregnancy Considerations. Available from: https://www.cdc.gov/poxvirus/monkeypox/clinicians/pregnancy.html#:~:text=Vaccination%20with%20JYNNEOS%20is%20contraindicated%2C%20and%20viral%20vaccine%20is%20not%20recommended%20for%20pregnant%20women. [Accessed 22 August 2022].

44. Badell ML, Meany-Delman D, Tuuli MG, Rasmussen SA, Petersen BW, Sheffield JS, et al. Risks associated with smallpox vaccination in pregnancy. Obstet Gynecol. 2015;125:1439–51.